Cargando…
Immune response to racotumomab in a child with relapsed neuroblastoma
Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-gly...
Autores principales: | Sampor, C., Guthmann, M. D., Scursoni, A., Cacciavillano, W., Torbidoni, A., Galluzzo, L., Camarero, S., Lopez, J., de Dávila, M. T. G., Fainboim, L., Chantada, G. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526767/ https://www.ncbi.nlm.nih.gov/pubmed/23267436 http://dx.doi.org/10.3389/fonc.2012.00195 |
Ejemplares similares
-
Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer
por: Scursoni, Alejandra M., et al.
Publicado: (2011) -
Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides – preclinical and clinical data
por: Vázquez, Ana M., et al.
Publicado: (2012) -
Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer
por: Segatori, Valeria I., et al.
Publicado: (2012) -
Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotype antibody targeting NeuGcGM3
por: Guthmann, Marcelo D., et al.
Publicado: (2013) -
Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression in Patients Receiving Racotumomab Immunotherapy
por: Uskent, Necdet, et al.
Publicado: (2020)